Synthetic Toll-like receptor 4 agonist enhances vaccine efficacy in an experimental model of toxic shock syndrome.
The development of new protein subunit vaccines has stimulated the search for improved adjuvants to replace traditional aluminum-containing products. We investigated the adjuvant effects of a synthetic Toll-like receptor 4 (TLR4) agonist on vaccine efficacy in an experimental model of toxic shock syndrome. The TLR4 agonist E6020 has a simplified structure consisting of a hexa-acylated acyclic backbone. The vaccine examined is a recombinantly attenuated form of staphylococcal enterotoxin B (STEBVax). Using cells stably transfected with TLRs, E6020 transduced signals only through TLR4, suggesting monospecificity, while Escherichia coli 055:B5 lipopolysaccharide activated both the TLR2/6 heterodimer and TLR4. Coadministration of E6020 with STEBVax, by the intramuscular or intranasal route, induced significant levels of immunoglobulin G (IgG) in BALB/c mice. Further, increased IgG production resulted from the combination of E6020 with aluminum hydroxide adjuvant (AH). The antibody response to the vaccine coadministered with E6020 was a mixed Th1/Th2 response, as opposed to the Th2-biased response obtained with AH. Mice vaccinated with STEBVax coadministered with AH, TLR4 agonists, or a combination of both adjuvants were protected from toxic shock. Our data demonstrate the effectiveness of the synthetic TLR4 agonist E6020 as an alternative adjuvant for protein subunit vaccines that may also be used in combination with traditional aluminum-containing adjuvants.
Morefield
Garry L
GL
Laboratory of Molecular Immunology, U.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA. ulrich@ncifcrf.gov
Hawkins
Lynn D
LD
Ishizaka
Sally T
ST
Kissner
Teri L
TL
Ulrich
Robert G
RG
D000276:Adjuvants, Immunologic; D000536:Aluminum Hydroxide / Q000276:immunology / Q000494:pharmacology; D000818:Animals; D001428:Bacterial Vaccines / Q000276:immunology*; D016207:Cytokines / Q000096:biosynthesis / Q000276:immunology; D004768:Enterotoxins / Q000276:immunology*; D007136:Immunoglobulins / Q000097:blood; D008070:Lipopolysaccharides / Q000276:immunology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D023421:Models, Animal; D012772:Shock, Septic / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control*; D015398:Signal Transduction; D013211:Staphylococcus aureus / Q000276:immunology*; D018417:Th1 Cells / Q000276:immunology; D018418:Th2 Cells / Q000276:immunology; D051195:Toll-Like Receptor 2 / Q000276:immunology; D051197:Toll-Like Receptor 4 / Q000819:agonists* / Q000276:immunology; D051216:Toll-Like Receptor 6 / Q000276:immunology
D000276:Adjuvants, Immunologic; D001428:Bacterial Vaccines; D016207:Cytokines; D004768:Enterotoxins; D007136:Immunoglobulins; D008070:Lipopolysaccharides; C493487:Tlr4 protein, mouse; D051195:Toll-Like Receptor 2; D051197:Toll-Like Receptor 4; D051216:Toll-Like Receptor 6; C031818:enterotoxin B, staphylococcal; D000536:Aluminum Hydroxide
Mol Med Today. 2000 Mar;6(3):125-32
10689316
Mol Syst Biol. 2006;2:2006.0015
16738560
J Immunol. 2000 Jul 15;165(2):618-22
10878331
Trends Microbiol. 2000 Oct;8(10):452-6
11044679
J Immunol. 2001 Jan 1;166(1):249-55
11123299
Cell Signal. 2001 Feb;13(2):85-94
11257452
Vaccine. 2001 Oct 12;20(1-2):59-66
11567746
Infect Immun. 2002 Feb;70(2):692-701
11796601
J Pharmacol Exp Ther. 2002 Feb;300(2):655-61
11805229
Scand J Immunol. 2002 Mar;55(3):293-303
11940236
Vaccine. 2003 Feb 14;21(9-10):961-70
12547609
Curr Mol Med. 2003 Jun;3(4):373-85
12776992
Eur J Immunol. 2003 Jul;33(7):1767-75
12811836
Clin Immunol. 2003 Jul;108(1):51-9
12865071
Nat Immunol. 2004 Oct;5(10):987-95
15454922
Johns Hopkins Med J. 1969 Jun;124(6):291-5
4895520
Nat Struct Biol. 1995 Jul;2(7):554-60
7664123
Trends Microbiol. 1995 Dec;3(12):463-8
8800837
Dev Biol Stand. 1996;87:113-24
8854008
Curr Opin Immunol. 1997 Feb;9(1):4-9
9039775
Vaccine. 1998 Nov;16(19):1857-64
9795392
Science. 1998 Dec 11;282(5396):2085-8
9851930
J Biol Chem. 1999 Apr 16;274(16):10689-92
10196138
Vaccine. 2006 Mar 6;24(10):1665-9
16246468
J Immunol. 2000 Jun 1;164(11):5998-6004
10820283